MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, UTHR made $799,500K in revenue. $338,700K in net income. Net profit margin of 42.36%.

Income Overview

Revenue
$799,500K
Net Income
$338,700K
Net Profit Margin
42.36%
EPS
$7.16
Unit: Thousand (K) dollars
Revenue Breakdown
    • Tyvaso DPI
    • Nebulized Tyvaso
    • Orenitram
    • Others
Revenue Breakdown
    • US
    • Non Us

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Total revenues
799,500 798,600 794,400 748,900
Cost of sales
100,900 87,600 92,500 83,100
Research and development
127,500 134,000 149,000 103,500
Selling, general, and administrative
182,600 212,500 170,100 219,200
Total operating expenses
411,000 434,100 411,600 405,800
Operating income
388,500 364,500 382,800 343,100
Interest income
46,400 51,300 51,100 49,800
Interest expense
3,000 7,300 6,100 10,100
Other income, net
6,100 -100 -4,300 5,800
Total other income, net
49,500 43,900 40,700 45,500
Income before income taxes
438,000 408,400 423,500 388,600
Income tax expense
99,300 98,900 101,300 79,500
Net income
338,700 309,500 322,200 309,100
Basic (in dollars per share)
7.73 6.86 7.18 6.93
Basic (in shares)
43,800,000 45,100,000 44,900,000 44,600,000
Diluted (in dollars per share)
7.16 6.41 6.63 6.39
Diluted (in shares)
47,300,000 48,300,000 48,600,000 48,400,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Product And ServiceOther$6,900K Adcirca$9,700K Unituxin$47,900K Orenitram$131,100K Remodulin$125,900K Nebulized Tyvaso$141,800K Tyvaso DPI$336,200K Other income, net$6,100K Interest income$46,400K Total revenues$799,500K Total other income,net$49,500K Operating income$388,500K Interest expense$3,000K Total operatingexpenses$411,000K Income before incometaxes$438,000K Selling, general, andadministrative$182,600K Research and development$127,500K Cost of sales$100,900K Net income$338,700K Income tax expense$99,300K

UNITED THERAPEUTICS Corp (UTHR)

UNITED THERAPEUTICS Corp (UTHR)